These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24007858)

  • 1. Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Deriu L; Lepori T; Maccioni R; Milia P; Sarritzu E; Tusconi M; Carpiniello B;
    Psychiatry Res; 2013 Dec; 210(3):739-44. PubMed ID: 24007858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of schizoaffective disorder. Are there any differences with respect to schizophrenia?
    Pinna F; Sanna L; Perra V; Pisu Randaccio R; Diana E; Carpiniello B;
    Riv Psichiatr; 2014; 49(1):41-9. PubMed ID: 24572583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Tusconi M; Bosia M; Cavallaro R; Carpiniello B;
    BMC Psychiatry; 2013 Sep; 13():235. PubMed ID: 24294839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower subjective quality of life and the development of social anxiety symptoms after the discharge of elderly patients with remitted schizophrenia: a 5-year longitudinal study.
    Kumazaki H; Kobayashi H; Niimura H; Kobayashi Y; Ito S; Nemoto T; Sakuma K; Kashima H; Mizuno M
    Compr Psychiatry; 2012 Oct; 53(7):946-51. PubMed ID: 22554765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders.
    Schennach-Wolff R; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Jäger M; Möller HJ; Riedel M
    Eur Psychiatry; 2011; 26(5):284-92. PubMed ID: 20435447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia.
    Karow A; Moritz S; Lambert M; Schöttle D; Naber D;
    Eur Psychiatry; 2012 Aug; 27(6):401-5. PubMed ID: 21570262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
    Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders.
    Pinna F; Deriu L; Diana E; Perra V; Randaccio RP; Sanna L; Tusconi M; Carpiniello B;
    Ann Gen Psychiatry; 2015; 14():6. PubMed ID: 25699085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
    Byerly MJ; Nakonezny PA; Rush AJ
    Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy.
    Pinna F; Fiorillo A; Tusconi M; Guiso B; Carpiniello B
    Int J Ment Health Syst; 2015; 9():37. PubMed ID: 26526168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients.
    Balestrieri M; Giaroli G; Mazzi M; Bellantuono C
    Pharmacopsychiatry; 2006 May; 39(3):81-4. PubMed ID: 16721695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
    Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.
    Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A
    BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.